Rodenstock reports 2023 revenue of €506.1 million and completes eyewear divestiture

Rodenstock Group announced its financial results for fiscal year 2023 in May 2024, reporting consolidated pro-forma net sales of €506.1 million, a slight increase from €505.3 million the previous year. Recurring EBITDA rose by €0.3 million to €122.3 million on a comparable basis. The company attributed this performance to an 8% sales growth in its B.I.G. VISION® biometric progressive lens portfolio and the successful launch of MyCon® lenses for children in Europe. The sale of the Rodenstock eyewear business marked the completion of its transformation into a pure-play Med-Tech company. Despite challenging macroeconomic conditions, including inflation and geopolitical tensions, management expects positive development to continue throughout 2024 based on operational efficiencies and further innovations.